Neoadjuvant Durvalumab + Chemo: Surgical Outcomes in Resectable NSCLC | Dr. Shubham Garg | CRSF

Adherence & outcomes of neoadjuvant immunotherapy in resectable NSCLCПодробнее

Dr Shubham Garg Segmentectony Versus Wedge Resection for Stage Non Small Cell Lung Cancer A Meta anaПодробнее

Panel Discussion | Dr Shubham Garg Management of Early Lung CancerПодробнее

CRSF 7 Masterclass | Dr Nivedita Chakarborty: Response Assessment After Chemotherapy & ImmunotherapyПодробнее

CheckMate 816: addressing unanswered questions on surgical outcomes following neoadjuvant chemo-IOПодробнее

Surgical outcomes from CheckMate 816: NIVO plus chemo vs chemo alone as neoadjuvant treatment fo...Подробнее

Lung Cancer Treatment in India | Best explained by Dr. Shubham GargПодробнее

Surgical outcomes from the Phase III CheckMate 816 trialПодробнее

Head and Neck Cancer Awareness by Dr. Shubham GargПодробнее

Adjuvant Pembrolizumab, Durvalumab, and More Considerations From UC Trials Presented at ESMO 2024Подробнее

The impact of durvalumab for resectable non-small cell lung cancerПодробнее

Osimertinib and Uncommon EGFR Mutations: Dr. Nieva Shares Insights From Real-World StudyПодробнее

STRONG: fixed-dose durvalumab for UTCПодробнее

PACIFIC trial updates: durvalumab after chemotherapy in NSCLCПодробнее

Surgical endpoints are needed in lung cancer trials of neoadjuvant therapyПодробнее

SANO-trial: neoadjuvant chemo-RT followed by surgery vs. active surveillance for oesophageal cancerПодробнее

Durvalumab Following Chemoradiotherapy and SurgeryПодробнее

Cataract Quiz: Retained lens fragment. What is your next move?Подробнее

Shastho Bondhu | LIVE with Dr. Shubham Garg | Surgical OncologyПодробнее